| Begin Date |
End Date |
Title |
| 12-16-2019 |
12-15-2024 |
1705
|
| 05-31-2019 |
05-30-2024 |
BMT CTN 1703/1801
|
| 05-28-2019 |
05-27-2024 |
CTRL-ALT-D
|
| 05-24-2019 |
05-23-2024 |
BMTCTN1704
|
| 09-27-2018 |
07-31-2021 |
Self-Management of Psychoneurological Symptoms in HCT Su
|
| 10-26-2017 |
10-25-2022 |
BMT CTN1502
|
| 08-29-2017 |
08-28-2022 |
EA4151
|
| 07-27-2017 |
06-30-2024 |
Wingard - BMT CTN Renewal
|
| 03-24-2017 |
03-23-2022 |
Miscellaneous Donors Project
|
| 09-30-2016 |
09-29-2021 |
BMT CTN 1501
|
| 07-06-2016 |
07-05-2023 |
A051301/BMT CTN 1201
|
| 10-19-2015 |
05-31-2017 |
A Randomized Recruitment Intervention Trial
|
| 09-15-2015 |
02-15-2022 |
Easy-to-Read Informed Consent (ETRIC) for Hematopoietic
|
| 05-21-2015 |
05-20-2018 |
Randomized study of individualized care plans
|
| 05-01-2015 |
04-30-2016 |
BMT CTN LTFU
|
| 04-01-2015 |
03-31-2021 |
BMT CTN 1301
|
| 07-01-2014 |
06-30-2019 |
Clinical Study Protocol Rider #1203
|
| 05-14-2014 |
05-13-2019 |
CTN1102: A Multi-Center Biologic Assignment Trial Compa
|
| 09-01-2013 |
09-30-2016 |
Individualized Care Plans for Hematopoietic Cell Transpl
|
| 07-01-2013 |
12-31-2019 |
Re-MATCH
|
| 05-01-2013 |
04-30-2020 |
Proposal 1202: Prospective Multi-Center Cohort for the
|
| 08-01-2012 |
07-01-2016 |
Phase II Study of Combination of Hyper-CVAD and D
|
| 04-01-2012 |
03-31-2021 |
PROTOCOL 1101 A Multi-Center, Phase III, Randomized
|
| 08-08-2011 |
06-30-2017 |
Core Clinical Consortium for Blood and Marrow Transplant..
|
| 03-29-2011 |
06-28-2012 |
Protocol 09-SQOL: Pilot study to assess the feasibility
|
| 12-29-2010 |
12-31-2019 |
Protocol 0804: A Phase II study of reduced-intensity all
|
| 12-29-2010 |
04-06-2016 |
Protocol 0901: A Randomized, Multi-Center, Phase III Stu
|
| 10-20-2010 |
10-18-2017 |
F014160: Support Teaching and Research Programs at UF
|
| 09-15-2010 |
11-19-2012 |
A Phase III Randomized, Multicenter Trial Testing Whethe
|
| 09-03-2010 |
08-02-2016 |
Protocol 0803: High Dose Chemotherapy with Autologous
|
| 08-04-2010 |
08-04-2015 |
A Research Database for the Hematopietic Stem Cell Trans
|
| 07-01-2010 |
06-30-2019 |
F002418: Support ESC devoted to Cancer Research,
|
| 04-29-2010 |
04-29-2016 |
Protocol#0702 A Trial of Single AutologousTransplant
|
| 02-03-2010 |
02-03-2022 |
Protocol 0801: A Phase II/III Randomized, Multicenter Tr
|
| 02-03-2010 |
02-17-2016 |
Protocol 0802: A Multi-Center, Randomized, Double Blind,
|
| 06-04-2009 |
06-04-2015 |
Protocol 0701: A Phase II Trial of Non-Myeloablative All
|
| 08-13-2008 |
06-01-2012 |
Protocol 0603: A Multi-Center, Phase II Trial of Nonmyel
|
| 08-13-2008 |
06-01-2012 |
Protocol 0604: A Multi-Center, Phase II Trial of Non-Mye
|
| 06-01-2008 |
05-31-2010 |
Mycology Research Unit; In Vivo Induced Fungal Antigens
|
| 05-20-2008 |
05-20-2017 |
Protocol #0703: A Phase II Study of Tandem Autologous
|
| 01-01-2008 |
05-31-2009 |
Mycology Research Unit: In ViVO Induced Fungal Antigens
|
| 07-01-2007 |
06-30-2019 |
Umbilical Cord Research
|
| 05-30-2007 |
02-29-2016 |
Clinical Laboratory Diagnostics for Invasive Aspergillos
|
| 03-08-2007 |
11-30-2008 |
Sample Collection, Processing and Clinical Trials - LUPR
|
| 02-22-2007 |
02-22-2019 |
Protocol 0502: A Phase II Study of Allogenic Transplant
|
| 02-22-2007 |
02-22-2016 |
Protocol 0402 ...Comparing sirolimus/tacrolimus with...
|
| 02-22-2007 |
02-22-2016 |
Protocol 0501: Multi-center, Open Label, Randomized Tria
|
| 01-01-2007 |
02-29-2012 |
UFCC for Cardiovascular Cell Therapy Research Network
|
| 12-01-2006 |
12-01-2015 |
Protocol # 0201: A Phase III Randomized, Multicenter Stu
|
| 12-01-2006 |
12-01-2015 |
Protocol #0401: Phase III Rituxan/BEAM vs. Bexxar/BEAM
|
| 12-01-2006 |
11-07-2012 |
Protocol # 0102: A Trial of Tandem Autologous Stem Cell
|
| 12-01-2006 |
08-18-2012 |
Protocol 0403: A Phase III, Randomized Double-Blind, Pla
|
| 09-29-2006 |
07-31-2007 |
NHLBI Blood and Marrow Transplant Clinical Research Netw
|
| 02-15-2006 |
08-06-2009 |
T00008 Renal Cell Carcinoma
|
| 09-01-2005 |
09-28-2006 |
CORE CLINICAL CENTER FOR BMT CLINICAL RESEARCH NETWORK
|
| 04-25-2005 |
02-15-2010 |
Protocol #0302 Initial systemic treatment of acute GVHD
|
| 11-15-2004 |
02-15-2008 |
OPEN-LABEL, LIMITED ACCESS PROTOCOL OF POSACONAZOLE IN
|
| 09-01-2004 |
08-31-2005 |
CORE CLINICAL CENTER FOR BMT CLINICAL RESEARCH NETWORK
|
| 06-15-2004 |
12-31-2007 |
MYCOLOGY RESEARCH UNIT: IN VIVO INDUCED FUNGAL ANTIGENS
|
| 04-06-2004 |
06-18-2008 |
MMF - FHCRC 1697
|
| 01-08-2004 |
08-31-2006 |
PATIENT COSTS - CLINICAL CENTER FOR BMT CLINICAL RESEAR
|
| 08-13-2003 |
05-23-2009 |
UFRF MISCELLANEOUS
|
| 08-04-2003 |
11-13-2003 |
A PROSPECTIVE RNDMZD DBL-BL MULTI-CTR PILOT STUDY OF THE
|
| 01-01-2003 |
12-31-2005 |
UNEXAMINED ISSUES FOR SURVIVORS and THEIR SPOUSES AFTER BL
|
| 07-01-2002 |
10-03-2003 |
IV BULSULFAN:ONCE DAILY INTRAVENOUS BULSULFAN (BULSULFEX
|
| 07-01-2002 |
06-14-2003 |
MULTICTR DBL-BL RNDMZD COMPAR STDY TO EVAL THE SAFETY TO
|
| 06-01-2002 |
05-31-2003 |
ENHANCING RECOVERY FROM BONE-MARROW TRANSPLANT
|
| 01-01-2002 |
09-29-2006 |
CDC PA 00055: SURVEILLANCE OF INVASIVE FUNGAL INFECTION
|
| 12-13-2001 |
12-13-2006 |
HEMATOLOGY/ONCOLOGY PRECEPTORSHIPS
|
| 11-14-2001 |
01-03-2004 |
A RETROSPECTIVE STUDY TO ESTABLISH AN HISTORICAL DATABAS
|
| 09-30-2001 |
08-31-2004 |
CORE CLINICAL CENTER FOR BMT CLINICAL RESEARCH NETWORK
|
| 09-25-2001 |
09-30-2008 |
VALGANCICLOVIR FOR THE PREVENTION OF LATE CMV INFECTION
|
| 08-23-2001 |
08-23-2004 |
FELLOWSHIP SUPPORT
|
| 10-03-2000 |
06-30-2002 |
IV BULSULFAN:ONCE DAILY INTRAVENOUS BULSULFAN (BULSULFEX
|
| 05-19-2000 |
05-18-2001 |
INDEPENDENT MEDICAL EDUCATION PROGRAM
|
| 04-28-2000 |
06-30-2002 |
MULTICTR DBL-BL RNDMZD COMPAR STDY TO EVAL THE SAFETY TO
|
| 04-06-2000 |
06-30-2005 |
EVAL OF DRUG INTERAC BTWN ORAL ITRACONZOLE and ORAL TACRO-
|
| 04-06-2000 |
06-14-2005 |
EVAL OF DRUG INTERACTION BTWN IV INTRCONAZOLE and CYCLOSPO
|
| 04-04-2000 |
11-21-2003 |
P00041 - OPEN-LABEL TREATMENT PROTOCOL FOR THE SAFETY and
|
| 01-19-2000 |
04-21-2002 |
EVALUATION OF THE BAXTER OPTIPRESS(TM)II IN THE SEPARATI
|
| 12-29-1999 |
10-20-2000 |
CHIMERIC 3- A MULTI-CTR, OPN-LBL RNDMZD ACTIVE CONTROLLE
|
| 09-01-1999 |
08-16-2002 |
ISOLEX 92004 302302-PERIPHERAL BLOOD STEM CELL TRANSPLAN
|
| 09-01-1999 |
08-27-2001 |
FK463-A PHASE 111 RNDMZD DBL-BL COMPARATIVE TRIAL OF FK4
|
| 08-09-1999 |
07-21-2001 |
A MULTICENTER PROSPECTIVE STUDY TO EVALUATE THE COSTS OF
|
| 07-16-1999 |
03-31-2001 |
GEN-HER-2-NEU - AUTOTRANSPLANTATION AND HER2 NEU ANTIBOD
|
| 07-05-1999 |
12-31-1999 |
PR96-22-022 RANDOMIZED STUDY OF PROCRIT (EPOETIN ALFA) I
|
| 07-01-1999 |
06-30-2003 |
QUALITY OF LIFE AND RELATIONSHIPS AFTER BMT
|
| 06-15-1999 |
04-03-2001 |
EFFICACY, SAFETY AND TOLERATION OF VORICONAZOLE VERSUS
|
| 04-08-1999 |
03-29-2001 |
A PHASE III OPN-LBL MULIT-CTR RNDOMZD COMPARATIVESTUDY O
|
| 02-25-1999 |
12-15-2000 |
A PILOT STUDY OF ALLOGENEIC BONE MARROW TRANSPLANTATION
|
| 10-21-1998 |
01-10-2001 |
DATA MANAGEMENT GRANT AGREEMENT
|
| 10-15-1998 |
02-16-2001 |
STUDY OF MOBILIZATION OF PERIPHERAL BLOOD STEM CELLS BY
|
| 07-01-1998 |
06-30-2010 |
HEMATOLOGY/ONCOLOGY FELLOWSHIP SUPPORT
|
| 02-24-1998 |
12-31-2000 |
RANDOMIZED, OPEN-LABEL COMPARATIVE MULTICENTER TRIAL OF
|
| 12-23-1997 |
11-15-1998 |
A PHASE I/II TRIAL TO DETERMINE THE OPTIMAL DOSE OF SC-7
|
| 08-28-1997 |
02-02-2001 |
A NONMYELOABLATIVE CONDITIONING REGIMEN OF INTENSIVE IMM
|
| 08-01-1997 |
07-31-1999 |
RNDMZD DBL-BL COMPAR TRL OF AMBISOME VS ABELCET IN THE
|
| 07-01-1997 |
01-31-2000 |
PROPHYLACTIC PLATELET TRANSFUSION IN HEMATOPOIETIC STEM
|
| 07-01-1997 |
06-30-1998 |
HEMATOLOGY/ONCOLOGY FELLOWSHIP SUPPORT
|
| 06-03-1997 |
03-01-1999 |
PHASE II/III RNDMZD, DBL-BL, PLCB-CNTRL TRL OF RECOMBINA
|
| 04-01-1997 |
02-22-2002 |
CTI 1034-A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-
|
| 01-31-1997 |
10-07-2000 |
PLACEBO-CONTROLLED TRIAL OF LISOFYLLINE IN HIGH RISK
|
| 10-15-1996 |
04-30-2001 |
PHASE I/II TRIAL TO DETERMINE THE MAXIMUM TOLERATED DOSE
|
| 10-14-1996 |
07-20-2001 |
ORPHAN MEDICAL, INC., PROTOCOL OMC-BUS-3 AND OMC-BUS 4 (
|
| 09-01-1996 |
08-30-2000 |
CLINICAL STUDY SUPPORT PERSONNEL AGREEMENT
|
Share